MedTrace Logo

An Open Label Study of the Genecept™ Assay in Treatment Resistant Depression

NCT01438242 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-03-23

No results posted yet for this study

Summary

The purpose of this study is to examine the potential impact of the assay in terms of depression severity as measured by change in Clinical Global Impressions (CGI) scale at 3 months.

Conditions

Interventions

DEVICE

Genecept Assay

Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders

Sponsors & Collaborators

  • Genomind, LLC

    lead INDUSTRY

Principal Investigators

  • Herbert Harris, MD, PhD · Rho, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01438242 on ClinicalTrials.gov